Indivior Share Discussion Threads

[gregmorg] 08/11/2024 14:09

Interesting times- end result with a few carpet baggers stirring the pot, I have no idea.

Sadly, I cannot say that the current CEO /management team has added any value- indeed, quite the opposite! Could anyone else really have done better? That is a question I ask myself! The last few years have been a complete disaster with lots of hope dashed every time, and I really would have loved it,AND be better off, were it any different!

[casholaa] 08/11/2024 11:32

Precarious.

[imjustdandy] 08/11/2024 05:31

I think you need to read the statements that were released onto the New York stock exchange last night. Takeover looks like best solution for the activist shareholders and the management for that matter. Management are toast without a takeover

[youngers] 07/11/2024 21:32

US closed at equivalent of £8.33 so should get another healthy bump in the morning

[imjustdandy] 07/11/2024 21:02

Be luck if this opens at 8.30am tomorrow. Total breakout

[imjustdandy] 07/11/2024 20:34

Will be over ten quid tomorrow maybe higher if a bid arrives

[casholaa] 07/11/2024 20:31

Indeed. I should have written to them too!

[imjustdandy] 07/11/2024 20:24

Looks like hostile takeover - article just out Indivior PLC (NASDAQ:INDV) soared 13% amid some takeover speculation as well as a letter from one of its largest holders.Oaktree Capital Management, Indivior's second-largest holder with a 7.5% stake, wrote a letter on Wednesday to the company's board discussing its disappointment with the company's performance."It is unacceptable that Indivior's stock price has plummeted more than 50% in the past year," Andrew Diego West, a managing director at Oaktree wrote in the letter. "In the face of that value destruction, Oaktree has attempted to engage constructively with the Company's Board to address shareholder concerns and improve shareholder value. However, instead of coming to the table collaboratively and demonstrating that they are taking action, the Board and management seem to be doubling down on a failing strategy, ignoring competitive threats and allowing costs to spiral."Indivior (INDV) on Thursday responded to the Oaktree letter."The Board has engaged actively with Oaktree in recent weeks on these topics, and remains open-minded about all proposals to enhance value creation," Indivior said in the statement. "The Board is focused on acting in the best interests of all shareholders as we continue to execute on our strategy."The Oaktree letter comes after the dual-listed U.S. drugmaker last month lowered its fiscal 2024 guidance for the second time in roughly three months, citing sales headwinds related to Sublocade, a prescription drug indicated for opioid use disorder.There's also speculation that the British biotech company may have attracted takeover interest, according to traders, who cited a Betaville "uncooked" alert that was circulating on Thursday.

[imjustdandy] 07/11/2024 20:21

Breaking new highs in USA

[imjustdandy] 07/11/2024 20:21

Oaktree are going to want action and board representation

[imjustdandy] 07/11/2024 20:19

Just released in USA. Board initial response . Board fighting for their life now. This is gonna get taken over very quickly

[imjustdandy] 07/11/2024 20:17

Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of IndiviorSource: PR Newswire (US)RICHMOND, Va., Nov. 7, 2024 /PRNewswire/ -- Indivior PLC (NASDAQ / LSE: INDV) the Board of Directors (the "Board") of Indivior plc ("Indivior" or the "Company") notes the publication today of a letter from Oaktree Capital Management LP ("Oaktree") to the Board of Indivior.Indivior (PRNewsfoto/Indivior)The Board has engaged actively with Oaktree in recent weeks on these topics, and remains open-minded about all proposals to enhance value creation. The Board is focused on acting in the best interests of all shareholders as we continue to execute on our strategy.Indivior looks forward to further engagement with Oaktree and other shareholders.

[imjustdandy] 07/11/2024 20:12

Flying in USA tonight

[hunter154] 07/11/2024 20:08

Let the games begin.
Cant wait.

[imjustdandy] 07/11/2024 19:05

Wow - this is really in play with serious activist shareholders with meaningful stakes.

[imjustdandy] 07/11/2024 19:03

Board of Directors
Indivior PLC
10710 Midlothian Turnpike, Suite 125
North Chesterfield, Virginia 23235

To the Members of the Board of Directors:

As you know, Oaktree Capital Management, L.P. (“Oaktree̶1;, “we” or “us”) advises certain funds that, in aggregate, own approximately 7.5% of the ordinary shares of Indivior PLC (“IndiviorR21; or the “Company”;), making us one of the Company’s largest shareholders.

It is unacceptable that Indivior’s stock price has plummeted more than 50% in the past year. In the face of that value destruction, Oaktree has attempted to engage constructively with the Company’s Board to address shareholder concerns and improve shareholder value. However, instead of coming to the table collaboratively and demonstrating that they are taking action, the Board and management seem to be doubling down on a failing strategy, ignoring competitive threats and allowing costs to spiral. The Board and management’s actions, or lack thereof, have caused Indivior to underperform the S&P Composite 1500 Pharmaceuticals Select Industry Index by (68%), (71%) and (77%), over a 1-year, 2-year and 3-year period respectively.1

Rather than focusing on Indivior’s core product, Sublocade, the Company spent valuable time and money on unproductive acquisitions, a now-discontinued business line, and excessive R&D. All the while, the Company essentially disregarded Brixadi’s entrance into the market by failing to take basic steps to protect Sublocade’s competitive position. As an example, the Company waited seven years after Sublocade’s initial FDA approval and more than a year after its competitor’s entry into the market before submitting its prior approval supplements to the FDA for Rapid Induction and Alternative Injection Sites – a pivotal step that would have solidified Sublocade’s dominant position and subdued the competitive threat from Brixadi. As a result, shareholders have suffered a more than 50% loss.

Indivior’s communications regarding its 2024 financial guidance serve as a telling example. At Indivior’s May 23, 2024 analyst teach-in event, management reiterated its full-year and long-term guidance metrics. Six weeks after that, management lowered its financial guidance: they cited Medicaid redetermination and a litany of other reasons but continued to dismiss the increasingly obvious competitive threat from Brixadi. Five months later, management took down guidance again, finally appearing to acknowledge an aggressive competitor. Management either didn’t recognize the competitive threat, or worse, they failed to appropriately alert the investing public about it.

To be clear, we strongly believe in the Company’s mission to alleviate the severe human suffering brought about by the opioid crisis and Sublocade’s key role. However, the rapid decline of shareholder value and the events of the past year – including a lack of focus and accountability by the Board and management, as well as failure to recognize and counter such a clear competitive threat – have exacerbated investor concerns around the Company’s strategy and the Board’s willingness and ability to hold management accountable.


1 As of November 5, 2024.

1

Oaktree Capital Management, L.P.
333 South Grand Avenue, 28th floor
Los Angeles, CA 90071
p [phone]
oaktreecapital.com
The Company must take immediate steps to address the following key concerns:

1)
Fix Capital Allocation Strategy and Cost Structure

Indivior’s capital allocation strategy has not produced results.

•
Opiant: the Company acquired Opiant in March 2023 for $145 million, which has yet to generate meaningful revenue from its key product, Opvee, despite it receiving FDA approval in May 2023.

•
Perseris: after significant R&D and operational expenses, management announced that it would discontinue sales and marketing of the product in July 2024, less than two months after reiterating guidance of peak sales of $200 to $300 million.

•
Manufacturing site: an $85 million investment2 to insource Sublocade and Perseris production seems misguided given the fate of Perseris and the minimal existing internal manufacturing process and know-how.

Indivior’s cost structure is bloated.

•
Costs continue to soar: from fiscal-year 2018 to 2023,adjusted operating expenses have increased by over 19% while revenue increased by only 4%.3

•
Operating expenses far exceed peers: Indivior’s operating expenses (excluding R&D) as a percentage of revenue have averaged almost 1400 basis points higher than its peers over the last five years.4

2)
Hold Management Accountable

The Company’s pattern of missteps must end.

•
The Board seemingly failed to push management to prepare for Brixadi’s market entry, despite common understanding of Brixadi’s desire (dating as far back as 2014) to compete with Sublocade in the U.S. market. Furthermore, the Company:

o
Failed to timely counter potential, but addressable, weaknesses of Sublocade (the drug’s shelf life and FDA approval for rapid induction and alternate injection sites).

o
Didn’t appropriately prepare for competition in the criminal justice system channel, which led to the Company losing a material contract.

•
The management team has fallen short in its communication with the market, consistently understating material financial impacts, often despite direct questions on the subject. For example, they:

o
Stated there would be no impact on guidance from Medicaid redetermination disenrollments, then a few months later cited these disenrollments as a reason for the Company’s reduction in its financial outlook.

o
Said there would be no impact on financial performance from competition, then blamed competition for poor financials just a few months later.

2 Per November 9, 2023, investor presentation slide 11: $5.5 million upfront consideration, $30 million in assumed contract liabilities and capital expenditures of $45 to $55mm over the next three years.
3 Figures in aggregate.
4 Peers include Alkermes PLC, Jazz Pharmaceuticals PLC, Supernus Pharmaceuticals Inc., Pacira BioSciences Inc., Neurocrine Biosciences Inc., Collegium Pharmaceutical Inc. and Endo Inc.

2

Oaktree Capital Management, L.P.
333 South Grand Avenue, 28th floor
Los Angeles, CA 90071
p [phone]
oaktreecapital.com
3)
Align Board with Shareholders

We are deeply concerned that the Board has failed to hold management, and themselves, accountable for the Company’s failures and destruction of shareholder value. Further, the non-executive members of the Board hold no meaningful amount of stock, and, unlike most U.S.-listed companies, the Company does not promote alignment with shareholders by compensating non-executive directors in stock.

We believe that the Board must address these issues immediately and work with us to refresh the Board with directors who are committed to taking all steps necessary to improve shareholder value and hold management accountable as they seek to address the Company’s performance.

While we remain interested in working constructively with the Board, we believe it is evident that shareholders are extremely concerned about Indivior’s performance and direction and would support action to effectuate change if necessary.

We look forward to continuing our communications in the coming weeks.


Andrew Diego West
Managing Director
Value Opportunities
Oaktree Capital Management, L.P.

3

[hunter154] 07/11/2024 18:35

The news is really good.
Apparently, Howard Marks, who is a large holder has written to the Board and asked for. Shake-up. About time

[imjustdandy] 07/11/2024 16:32

So so undervalued.

[bulltradept] 07/11/2024 15:48

T/O Rumours?

[davius] 07/11/2024 15:37

Odd little spike this afternoon, have taken that and sold the last of my shares at 753p. Best of luck for anyone still holding.

[tsmith2] 24/10/2024 14:52

P/E of just 5, prolific cash cow, strong growth prospects..too cheap

[the grumpy old men] 24/10/2024 11:22

Ian Lyall
PROACTIVENEWS

Indivior shares motor 11% after reassuring update; brokers positive

Published: 11:50 24 Oct 2024 BST


Indivior PLC (LSE:INDV)’s share price jumped 11% after the company reaffirmed its full-year outlook despite recent challenges, including increased competition for its opioid addiction treatment, Sublocade.

In its third-quarter results, Indivior posted a 13% revenue increase to $307 million, with Sublocade sales rising 14% to $191 million.

The company addressed concerns over competitor Brixadi, stating it remains confident in Sublocade's leadership, which holds a mid-60% market share in key prescribing groups.

CEO Mark Crossley highlighted Sublocade’s differentiation, particularly in combating synthetic opioids, and reaffirmed the goal of achieving over $1.5 billion in peak revenue. Indivior is also streamlining its operations, aiming to cut operating expenses by up to $20 million in 2025.

"Headline [third quarter figures beat consensus due to strong Suboxone Film but Sublocade growth is flat QoQ [quarter-on-quarter]," said Jefferies in a note.

In late morning trade, the stock was up 74.5p at 725p. Jefferies says 'buy' up to 1,800p.

Fellow American bank Stifel restated its 'buy' and 1,400p price target, adding: "We are encouraged by the still more than 60% share for Sublocade by co-prescribers of both Sublocade and Brixadi, while the early and within-expectations settlement of the remaining antitrust cases is incrementally positive.

"After two profit warnings this year, we recognise the need to rebuild market confidence, but continue to believe market concerns implied by current low multiples...are overdone."

[martinmc123] 24/10/2024 10:16

4*
Indivior posted upbeat Q3 results and also announced that it had reached an expected settlement with certain end payors to resolve remaining antitrust cases. Total Q3 2024 net revenue (NR) of $307m was up +13% vs. Q3 2023 with ytd revenue up 11% to $889m. Of this SUBLOCADE® Q3 2024 NR of $191m was +14% vs. Q3 2023 taking YTD 2024 SUBLOCADE NR up to $562m which was +24% vs. YTD 2023. The impressive top line performance fed down to improved bottom line performance, Q3 2024 reported net income was $4m up from a Q3 2023...

...from WealthOracle


wealthoracle.co.uk/detailed-result-full/INDV/907